
Oscar Tahuahua/X
Jun 11, 2025, 13:02
Oscar Tahuahua Highlighted Nature Study on ICI Rechallenge in Advanced Lung Cancer
Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, shared a post on X about a recent article published in Nature by Li-Bo Tang et al.:
“Rechallenge with ICIs in adv. lung cancer: A retrospective multicenter study (N=124) showed modest benefit (OS 12.7m) with fewer irAEs.
Viable if prior ICI was stopped for toxicity/non-progression.
Figure highlights when not to reintroduce ICIs.”
Title: Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer
Journal: Nature
Authors: Li-Bo Tang, Ying-Long Peng, Ji Chen, Jia-Ting Li, Mei-Mei Zheng, Lv Wu, Chang Lu, Xue-Wu Wei, Dong-Xuan Cai, Zhi Guo, Zi-Rui Ren, Si-Di Lv, Yu Deng, Zhi-Hong Chen, Chong-Rui Xu, Qing Zhou
More posts featuring Oscar Tahuahua on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 11, 2025, 13:02